


**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims**

1. (currently amended) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a ~~CCR-2 chemokine receptor-2 antagonist~~.

2. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



wherein:

X is selected from the group consisting of:

-O-, -NR<sup>20</sup>-, -S-, -SO-, -SO<sub>2</sub>-, and -CR<sup>21</sup>R<sup>22</sup>-, -NSO<sub>2</sub>R<sup>20</sup>-,

-NCOR<sup>20</sup>-, -NCO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>CO<sub>2</sub>R<sup>20</sup>-, -CR<sup>21</sup>OCOR<sup>20</sup>-, -CO-,

where R<sup>20</sup> is selected from: hydrogen, C<sub>1</sub>-6 alkyl, benzyl, phenyl,

C<sub>3</sub>-6 cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1</sub>-3alkyl, C<sub>1</sub>-3alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1</sub>-6 alkyl, and trifluoromethyl,

where R<sup>21</sup> and R<sup>22</sup> are independently selected from: hydrogen, hydroxy, C<sub>1</sub>-6 alkyl, -O-C<sub>1</sub>-6alkyl, benzyl, phenyl, C<sub>3</sub>-6 cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1</sub>-3alkyl, C<sub>1</sub>-3alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1</sub>-6 alkyl, and trifluoromethyl;

R<sup>1</sup> is selected from:

-C<sub>1</sub>-6alkyl, -C<sub>0</sub>-6alkyl-O-C<sub>1</sub>-6alkyl-, -C<sub>0</sub>-6alkyl-S-C<sub>1</sub>-6alkyl-,  
-(C<sub>0</sub>-6alkyl)-(C<sub>3</sub>-7cycloalkyl)-(C<sub>0</sub>-6alkyl), hydroxy, -CO<sub>2</sub>R<sup>20</sup>, heterocycle,  
-CN, -NR<sup>20</sup>R<sup>26</sup>, -NSO<sub>2</sub>R<sup>20</sup>, -NCOR<sup>20</sup>, -NCO<sub>2</sub>R<sup>20</sup>, -NCOR<sup>20</sup>,  
-CR<sup>21</sup>CO<sub>2</sub>R<sup>20</sup>, -CR<sup>21</sup>OCOR<sup>20</sup>, phenyl and pyridyl,  
where R<sup>26</sup> is selected from: hydrogen, C<sub>1</sub>-6 alkyl, benzyl, phenyl, C<sub>3</sub>-6 cycloalkyl

where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C<sub>1</sub>-3alkyl, C<sub>1</sub>-3alkoxy, -CO<sub>2</sub>H, -CO<sub>2</sub>-C<sub>1</sub>-6 alkyl, and trifluoromethyl

where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents  
where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) -O-C<sub>1</sub>-3alkyl,
- (d) trifluoromethyl,
- (f) C<sub>1</sub>-3alkyl,
- (g) -O-C<sub>1</sub>-3alkyl,
- (h) -CO<sub>2</sub>R<sup>20</sup>,
- (i) -SO<sub>2</sub>R<sup>20</sup>,
- (j) -NHCOCH<sub>3</sub>,
- (k) -NHSO<sub>2</sub>CH<sub>3</sub>,
- (l) -heterocycle,
- (m) =O,
- (n) -CN,

and where the phenyl and pyridyl are unsubstituted or substituted with 1-3 substituents  
where the substituents are independently selected from: halo, hydroxy, C<sub>1</sub>-3alkyl, C<sub>1</sub>-3alkoxy and trifluoromethyl;

R<sup>2</sup> is selected from:

- (a) hydrogen,
- (b) hydroxy,
- (c) halo,
- (d) C<sub>1</sub>-3alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
- (e) -NR<sup>20</sup>R<sup>26</sup>,
- (f) -CO<sub>2</sub>R<sup>20</sup>,

- (g) -CONR<sub>2</sub>R<sub>26</sub>,
- (h) -NR<sub>2</sub>COR<sub>21</sub>,
- (i) -OCONR<sub>2</sub>R<sub>26</sub>,
- (j) -NR<sub>2</sub>CONR<sub>2</sub>R<sub>26</sub>,
- (k) -heterocycle,
- (l) -CN,
- (m) -NR<sub>2</sub>-SO<sub>2</sub>-NR<sub>2</sub>R<sub>26</sub>,
- (n) -NR<sub>2</sub>-SO<sub>2</sub>-R<sub>26</sub>,
- (o) -SO<sub>2</sub>-NR<sub>2</sub>R<sub>26</sub>, and
- (p) =O, where R<sup>2</sup> is connected to the ring via a double bond;

R<sup>3</sup> is oxygen or is absent;

R<sup>4</sup> is selected from:

- (a) hydrogen,
- (b) C<sub>1-6</sub>alkyl,
- (c) trifluoromethyl,
- (d) trifluoromethoxy,
- (e) chloro,
- (f) fluoro,
- (g) bromo, and
- (h) phenyl;

R<sup>5</sup> is selected from:

- (a) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro and optionally substituted with hydroxyl,
- (b) -O-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (c) -CO-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (d) -S-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (e) -pyridyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C<sub>1-4</sub>alkyl, and CO<sub>2</sub>R<sup>20</sup>,
- (f) fluoro,

- (g) chloro,
- (h) bromo,
- (i) -C<sub>4-6</sub>cycloalkyl,
- (j) -O-C<sub>4-6</sub>cycloalkyl,
- (k) phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of : halo, trifluoromethyl, C<sub>1-4</sub>alkyl, and CO<sub>2</sub>R<sup>20</sup>,
- (l) -O-phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of : halo, trifluoromethyl, C<sub>1-4</sub>alkyl, and CO<sub>2</sub>R<sup>20</sup>,
- (m) -C<sub>3-6</sub>cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (n) -O-C<sub>3-6</sub>cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (o) -heterocycle,
- (p) -CN, and
- (q) -CO<sub>2</sub>R<sup>20</sup>;

R<sup>6</sup> is selected from:

- (a) hydrogen,
- (b) C<sub>1-6</sub>alkyl, and
- (c) trifluoromethyl
- (d) fluoro
- (e) chloro, and
- (f) bromo;

R<sup>7</sup> is selected from:

- (a) hydrogen, and
- (b) C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>H, -CO<sub>2</sub>C<sub>1-6</sub>alkyl, and -O-C<sub>1-3</sub>alkyl;

R<sup>8</sup> is selected from:

- (a) hydrogen,
- (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,

- (c) fluoro,
- (d) -O-C<sub>1-3</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-3 fluoro, and
  - (e) C<sub>3-6</sub> cycloalkyl,
  - (f) -O-C<sub>3-6</sub>cycloalkyl,
  - (g) hydroxy,
  - (h) -CO<sub>2</sub>R<sup>20</sup>,
  - (i) -OCOR<sup>20</sup>,

or R<sup>7</sup> and R<sup>8</sup> may be joined together via a C<sub>2-4</sub>alkyl or a C<sub>0-2</sub>alkyl-O-C<sub>1-3</sub>alkyl chain to form a 5-7 membered ring;

R<sup>9</sup> is selected from:

- (a) hydrogen,
- (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,
- (c) CO<sub>2</sub>R<sup>20</sup>,
- (d) hydroxy, and
- (e) -O-C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C<sub>1-3</sub>alkoxy, hydroxy, -CO<sub>2</sub>R<sup>20</sup>,

or R<sup>8</sup> and R<sup>9</sup> may be joined together by a C<sub>1-4</sub>alkyl chain or a C<sub>0-3</sub>alkyl-O-C<sub>0-3</sub>alkyl chain to form a 3-6 membered ring;

R<sup>10</sup> is selected from:

- (a) hydrogen, and
- (b) C<sub>1-6</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (c) fluoro,
- (d) -O-C<sub>3-6</sub>cycloalkyl, and
- (e) -O-C<sub>1-3</sub>alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,

or R<sup>8</sup> and R<sup>10</sup> may be joined together by a C<sub>2-3</sub>alkyl chain to form a 5-6 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and C<sub>1-3</sub>alkoxy,


or R<sup>8</sup> and R<sup>10</sup> may be joined together by a C<sub>1-2</sub>alkyl-O-C<sub>1-2</sub>alkyl chain to form a 6-8 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and C<sub>1-3</sub>alkoxy,  
or R<sup>8</sup> and R<sup>10</sup> may be joined together by a -O-C<sub>1-2</sub>alkyl-O-chain to form a 6-7 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO<sub>2</sub>R<sup>20</sup>, C<sub>1-3</sub>alkyl, and C<sub>1-3</sub>alkoxy;

n is selected from 0, 1 and 2;

the dashed line represents the optional presence of a second bond to form a double bond; and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

3. (previously presented) The method according to claim 2, wherein X is oxygen.

4. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



5. (New) The method of Claim 2, wherein R<sup>1</sup> is isopropyl, R<sup>2</sup> is hydrogen, R<sup>3</sup> is absent, R<sup>4</sup> is hydrogen, R<sup>5</sup> is -CF<sub>3</sub>, R<sup>6</sup> is hydrogen, R<sup>7</sup> is hydrogen, R<sup>8</sup> is -OCH<sub>3</sub>, R<sup>9</sup> is hydrogen, X is oxygen, R<sup>10</sup> is hydrogen, n is 1, and the dashed line is absent, so that the 5-membered ring has no double bonds.